Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LAMAinDiab - Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes - a Randomized Cross-over Clinical Trial

NCT05957055 is registered in ClinicalTrials.gov with Medical University of Lodz as lead sponsor.

NCT NCT05957055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LAMAinDiab - Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes - a Randomized Cross-over Clinical Trial
Lead sponsor
Medical University of Lodz
Phase
Phase 2
Overall status
Recruiting
Start date
February 5, 2024
Completion date
December 1, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit disorder with hyperactivity, diabetes mellitus, type 1